Lumosa Therapeutics Co. Ltd Financials

Market Capitalization TW$39.15 Billion as of Jan. 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	-161.59
Forward PE	-126.74
Price to Sales TTM	TW$820.63
Price to Book MRQ	TW$27.97
Enterprise to Revenue	1158.07
Enterprise to EBITDA	-164.90

Financial Reports as of Sep. 30, 2024

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2024-09-30
Profit Margin	72.88%
Operating Margin	-858.53%
Return on Assets TTM	-12.56%
Return on Equity TTM	-19.22%

Income Statement

Revenue TTM	TW$47,713,000
Revenue per Share TTM	TW$0.29
Quarterly Revenue Growth	-40.10%
Gross Profit TTM	TW$41,481,000
EBITDA	TW$-335,080,992
Net Income to Common TTM	TW$-280,719,008
Diluted EPS TTM	TW$-2.40
Quarterly Earnings Growth YoY	%

Balance Sheet

Total Cash MRQ	TW$609,046,016
Total Cash per Share MRQ	TW$3.69
Total Debt MRQ	TW$
Total Debt to Equity MRQ	0.76
Current Ratio MRQ	4.09
Book Value per Share MRQ	TW$8.49

Cash Flow

Operating Cash Flow TTM	TW$-283,511,008
Levered Free Cash Flow TTM	TW$-179,409,872

6535 Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	164,862,000
Float Shares	89,228,117
Avg 10 Volume	733,700
Avg 30 Volume	None
Shares Short	None
Short Ratio
Short % of Shares	%
% Held by Insiders	47.01%
% Held by Institutions	5.22%

Stock Price Summary

Beta	0.36
Fifty Two Week Low	TW$123.00
Fifty Two Week High	TW$400.00
Fifty Two Week Change	46.20%
Day 50 MA	TW$334.69
Day 200 MA	TW$235.92

Dividends and Splits

Forward Annual Dividend Rate	TW$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	TW$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date